Bevacizumab biosimilar (CTTQ Pharma)

贝伐珠单抗生物类似药（正大天晴）

Report date: 2026/03/11 20:02:12

Base Information

Drug NameBevacizumab biosimilar (CTTQ Pharma)
Drug Alias Name贝伐珠单抗生物仿制药（正大天晴）贝伐赛珠单抗生物仿制药（正大天晴）贝伐人源化单抗生物仿制药（正大天晴）贝伐单抗生物仿制药（正大天晴）安倍斯 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[8] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsGlioblastoma
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungColorectal NeoplasmsGlioblastoma
Original Approved Country/TerritoryMainland China
Original Approved Date2023/02/28
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 
Inactive IndicationsRectal NeoplasmsNeoplasms

Other Information

ATC CodeL01XC07
Related LinksN/A